Study population
bleeding, arteriovenous malformations, vascular aneurysms, malignant tumors, venous thromboembolism, hypersensitivity
BLEEDING, HEMORRHAGIC STROKE, DISEASE, COVID-19 INFECTION, MALIGNANT TUMORS, PEPTIC ULCER, COAGULOPATHY, HEPARIN INDUCED THROMBOCYTOPENIA, ATRIAL FIBRILLATION, HYPERSENSITIVITY, IMPAIRED RENAL FUNCTION
The same inclusion and exclusion criteria were applied for patients included either in the interventional or in the observational arms. Inclusion criteria were: age >  = 18 y; hospital admission; microbiologically confirmed COVID-19 infection; moderate-severe disease according to study definitions (see below); and ability to provide consent to participate and to use data for interventional study, only to use data for observational cohort. Patients were excluded in case of coagulopathy: INR > 1.5, aPTT ratio > 1.4; impaired renal function (clearance to creatinine less than 15 ml/min); known hypersensitivity to heparin; history of heparin induced thrombocytopenia; presence of an active bleeding or condition susceptible of bleeding in presence of anticoagulation (e.g. recent hemorrhagic stroke, peptic ulcer, malignant tumors at high risk of bleeding, recent neurosurgery or ophthalmic surgery, vascular aneurysms, arteriovenous malformations); body weight < 45 or > 150 kg; concomitant anticoagulant treatment for other indications (e.g. atrial fibrillation, venous thromboembolism, prosthetic heart valves); dual antiplatelet therapy; pregnant or breast-feeding women.